24/7 Wall Street
04 Nov 2026, 17:47 UTC · 35m ago
Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone
Impact · against what's priced in
Novo Nordisk's dominant 80% NBRx share for its oral Wegovy provides a concrete volume catalyst to offset severe price erosion. For Eli Lilly, the data confirms a weaker-than-expected initial launch for its oral pill, validating the bear case that competitive pressure from Novo will compress margins.
- LLY−0.30
Challenges what's priced in
- The price assumes
The bear case that GLP-1 concentration risk and competitive pressure from Novo Nordisk's oral Wegovy will compress margins
The data showing Novo Nordisk capturing 80% of new prescriptions—up from 65% in Q1—directly supports the bear case that Novo is winning the oral pill race, threatening Lilly's market share dominance.
What LLY's price assumes · Sep 10
